Literature DB >> 11903782

Guidelines for anticoagulation therapy for venous thromboembolism.

David K Cundiff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11903782      PMCID： PMC1494996          DOI： 10.1046/j.1525-1497.2002.11138.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  9 in total

1.  Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group.

Authors:  P Lindmarker; M Holmström
Journal:  J Intern Med       Date:  1996-12       Impact factor: 8.989

2.  A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process.

Authors:  P S Wells; J Hirsh; D R Anderson; A W Lensing; G Foster; C Kearon; J Weitz; R D'Ovidio; A Cogo; P Prandoni; A Girolami; J S Ginsberg
Journal:  J Intern Med       Date:  1998-01       Impact factor: 8.989

Review 3.  Oral anticoagulation in venous thromboembolism: decisions based on more than mere feelings.

Authors:  S Schulman
Journal:  J Intern Med       Date:  1999-04       Impact factor: 8.989

4.  Adherence to guidelines for oral anticoagulation after venous thrombosis and pulmonary embolism.

Authors:  D A Ganz; R J Glynn; H Mogun; E L Knight; R L Bohn; J Avorn
Journal:  J Gen Intern Med       Date:  2000-11       Impact factor: 5.128

5.  Silent pulmonary embolism in patients with deep venous thrombosis. Incidence and fate in a randomized, controlled trial of anticoagulation versus no anticoagulation.

Authors:  H K Nielsen; S E Husted; L R Krusell; H Fasting; P Charles; H H Hansen
Journal:  J Intern Med       Date:  1994-05       Impact factor: 8.989

6.  A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis.

Authors:  K Luomanmäki; S Grankvist; C Hallert; I Jauro; K Ketola; H C Kim; H Kiviniemi; H Koskivirta; L Sörskog; P Vilkko
Journal:  J Intern Med       Date:  1996-08       Impact factor: 8.989

Review 7.  Low molecular weight heparins.

Authors:  D Bergqvist
Journal:  J Intern Med       Date:  1996-08       Impact factor: 8.989

8.  Anticoagulant therapy in deep venous thrombosis. A randomized controlled study.

Authors:  H K Nielsen; S E Husted; L R Krusell; H Fasting; P Charles; H H Hansen; B O Nielsen; J B Petersen; P Bechgaard
Journal:  Thromb Res       Date:  1994-02-15       Impact factor: 3.944

9.  Inadequacy of intravenous heparin therapy in the initial management of venous thromboembolism.

Authors:  H N Lee; D J Cook; A Sarabia; R Hatala; A McCallum; D King; G H Guyatt; J Dobranowski; P Powers
Journal:  J Gen Intern Med       Date:  1995-06       Impact factor: 5.128
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.